ESRα Promoter Methylation May Modify the Association Between Lipid Metabolism and Type 2 Diabetes in Chinese Farmers

Guoyu Zhou 1,2, Lihua Liu 1, Xing Li 3, Xiangbo Hou 1, Ling Wang 3, Renjie Sun 1, Hui Huang 1, Zhiyuan Li 1, Wenjie Li 3, Chongjian Wang 4 and Yue Ba 1,2*

1 Department of Environment Health & Environment and Health Innovation Team, School of Public Health, Zhengzhou University, Zhengzhou, China, 2 Yellow River Institute for Ecological Protection & Regional Coordinated Development, Zhengzhou University, Zhengzhou, China, 3 Department of Nutrition and Food Health, School of Public Health, Zhengzhou University, Zhengzhou, China, 4 Department of Epidemiology and Biostatistics, School of Public Health, Zhengzhou University, Zhengzhou, China

Objective: This study is aimed to explore the potential association among the estrogen receptor alpha (ESRα) promoter methylation, lipid metabolism and the risk of type 2 diabetes mellitus (T2DM).

Methods: A total of 1143 rural residents were recruited randomly from Henan Province, China. The circulating methylation levels in ESRα promoter region were determined by quantitative methylation-specific polymerase chain reaction. Serum high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), total cholesterol (TC) and fasting plasma-glucose (FPG) were measured.

Results: The ESRα promoter methylation levels were negatively associated with HDL-C levels whether gender stratification was performed (P < 0.05) and positively correlated with LDL-C in men (P < 0.05). Each unit standard deviation (SD) increment in TG was associated with a 43% increase (95% CI: 1.25, 1.64) in the risks of T2DM in all participants, a 36% increase (95% CI: 1.13, 1.64) in the risks of T2DM in men and a 49% increase (95% CI: 1.21, 1.83) in the risks of T2DM in women. Furthermore, each SD increment in HDL-C was associated with a reduction of 25% (OR = 0.75, 95% CI: 0.58, 0.97) in the risks of T2DM in men, and the risk of T2DM in men may be more susceptible to HDL-C than that in women (P for interaction < 0.05). Additionally, we found that the risk of T2DM in participants with lower methylation levels (≤4.07%) were more susceptible to HDL-C (P for interaction < 0.05).

Conclusions: These findings suggested that lipid metabolism was associated with ESRα promoter methylation levels and the risk of T2DM. Besides, the levels of ESRα promoter methylation and gender can modify the association of HDL-C and T2DM.

Keywords: estrogen receptor alpha, DNA methylation, lipid metabolism, diabetes mellitus, farmers
BACKGROUND

Type 2 diabetes mellitus (T2DM) poses a worldwide public health problem with a continuously increasing prevalence in both developing and developed countries (1–3). More than half of patients with T2DM suffer from dyslipidemia (4). Diabetic dyslipidemia is mainly a mixed dyslipidemia with higher triglycerides (TG) and low density lipoprotein cholesterol (LDL-C), and lower of high density lipoprotein cholesterol (HDL-C) which can be observed before the onset of diabetes (5–7). The use of lipid-lowering therapy can improve lipid metabolism and prevent T2DM (8). Consequently, exploring the molecular mechanisms underlying abnormal lipid metabolism and T2DM pathogenesis is critical to develop therapeutic strategies for T2DM.

Several evidences indicate that estrogens can regulate lipid metabolism and protect mouse from β-cell apoptosis (9, 10). Estrogens deficiency can contribute to metabolic dysfunction, and then cause obesity and insulin resistance (11, 12). Additionally, the estrogens therapy has been revealed to have various beneficial effects by decreasing fasting glucose, increasing insulin sensitivity and secretion and reduce T2DM incidence in postmenopausal women (13, 14). Notably, the metabolic effects of estrogens are mediated by estrogen receptor alpha (ESRα) (15). Animal studies revealed that mice were more resistant to insulin after ESRα knockout (11). Furthermore, Ribas et al. (16) found that ESRα deficiency can increase fasting insulin levels, impairs glucose tolerance and results in skeletal muscle insulin resistance. As an important epigenetic modification, DNA methylation is a key regulator of gene expression. Additionally, the methylation of ESRα promoter is reported to reduce the expression of ESRα (17). Furthermore, abnormal DNA methylation were found to be associated with lipid metabolism disorders (17, 18). However, whether the alteration of ESRα promoter methylation affects human lipid metabolism and the risk of T2DM has not been explored.

Given these, in this study, we conducted a cross-sectional study in rural areas of Henan Province, and recruited 1,143 Chinese farmers to identify the association of ESRα promoter methylation, lipid metabolism and T2DM. With the development of targeted interventions for DNA methylation (19), this study can provide a theoretical basis for the screening of diabetes-susceptible populations and future precision therapy.

METHODS

Study Participants

A cross-sectional study was conducted in Wuzhi County of Henan Province in China by random sampling in 2013. Participants were excluded as the following: (1) people with type 1 diabetes; (2) secondary diabetes (drug-induced, chemically-induced, exocrine pancreatic insufficiency, and genetic defects); (3) gestational diabetes and rare forms of diabetes. Finally, a total of 1,143 local permanent residents were recruited in this study. The project was approved by the Institutional Review Board at Zhengzhou University. All participants were informed of the purpose of the study and provided written informed consent.

Outcome Variable

The diagnostic testing for T2DM was performed according to the criteria of World Health Organization (1999) (20) and the guidelines of American Diabetes Association (2002). All the nondiabetic people had normal glucose tolerance after an oral glucose tolerance test (OGTT).

Sampling and Data Collection

Trained investigators conducted a face-to-face interview with each participant using a standard questionnaire for obtaining information of demographic characteristics including age, gender, economic status, educational level, dietary habits and lifestyle (smoking and drinking, salt intake, physical activity, et, al). Among participants, those who had smoked at least 100 cigarettes in their lifetime were defined as “smoking”; those consuming any drink containing alcohol more than 12 times during the past 12 months were defined as “drinking.” A total of 10 mL fasting blood samples (5 ml of anticoagulative and 5 ml of non-anticoagulative) were collected from each participant. Serum samples were isolated from non-anticoagulative blood after centrifugation (3,000 rpm for 15 min) at 4°C and frozen at −80°C for subsequent analyses.

Measurement of Biochemical Parameters

The concentration (mmol/L) of HDL-C, LDL-C, TG, total cholesterol (TC) and FPG in serum samples were measured with direct method of catalase clearance, direct method of surfactant removal, glycerol phosphate oxidase-peroxidase (GPO-PAP), cholesterol oxidase-peroxidase (GHOD-PAP) and glucose oxidative method, respectively (21). Finally, 120 serum samples were randomly selected for repeated measurements. All analyses were run on an automatic biochemical analyzer (Kehua Bio-engineering Co., Ltd, Shanghai, China).

Measurement of ESRα Promoter Methylation

The genomic DNA was extracted from whole blood samples using a BioTeke Magnetic beads kit (Biotek Corporation, Beijing, China). The concentration of DNA samples was measured using a Nanodrop ND-2000 spectrophotometer (Thermo, MA, USA). Subsequently, the genomic DNA were treated with sodium bisulfite using an EZ DNA Methylation-Gold kit (Zymo Research, CA, USA). The putative promoter sequences of ESRα the sequence of the gene promoter region assumed to be 2,000 bp upstream from the ESRα start codon (22) were obtained from UCSC/Ensembl, and then primer sequences (methylated specific primers: L, 5′-CGT AGG TTT ACG GTT AGA TC GG-3′; R, 5′-ATA CAA TAA CAT CAA CGA ACT CGAA-3′; unmethylated specific primers: L, 5′-ATG GTT AGA TTG GTT TTT TTT TAGG-3′; R, 5′-ACA TCA ACA AAC TCA AAA ACA CACT-3′) were designed using the methylation primer design software (Methyl Primer Express v1.0). The ESRα
methylated promoter regions were analyzed using quantitative methylation-specific PCR on a MX3000P real-time PCR system (Agilent, Santa Clara, CA, USA). PCR amplification was performed in a 15 μl reaction mixture contained 5.5 μl of diluted DNA template (100 ng), 7.5 μl of 2× Power SYBR Green PCR Master Mixture (CWBio, Beijing, China), 2 μl of primer with a concentration of 1.25 μmol/L each. The PCR cycling parameters were as follows: 95°C for 10 min; 40 cycles for degeneration at 94°C for 15 s, annealing at 54°C for 30 s, and extension at 72°C for 30 s. Two negative controls (replace the DNA template with ddH2O) were set for each plate. The level of DNA methylation was calculated according to the formula: \(1/(1+2^{-\Delta Ct})\)×100%, where \(\Delta Ct = Ct(\text{unmethylated}) - Ct(\text{methylated})\) (23). Ct is the threshold of PCR cycle number at which the increase in fluorescent signal reaches a critical point. Each sample was analyzed in duplicate.

**Statistical Analysis**
The Student’s t-test, Wilcoxon test and Chi-square test were used to analyze the differences in normal/near-normal characteristics, other continuous variables and categorical variables between participants in T2DM group and non-diabetic group. We then utilized linear regression model to examine the association between ESRα methylation level and lipid metabolism. Besides, the association between T2DM and lipid metabolism (as well as ESRα methylation level) was estimated using binary logistic regression model. The linear trends across increasing quartiles of ESRα methylation level and lipid metabolism were estimated by treating the median of each quartile as a continuous variable. The quartiles of ESRα methylation and lipid metabolism are shown in **Supplementary Table 1**. After stratifying the participants according to the median of ESRα promoter methylation level, we analyzed the interactive effect of ESRα methylation and lipid metabolism on the risk of T2DM by adding an interaction term “ESRα methylation * lipid metabolism” to the logistic regression model. In addition, we performed other interactive analyses by adding an interaction term (“ESRα methylation*gender” or “lipid metabolism*gender”) to each models. According to the characteristics of the participants and the previous reports, we adjusted a variety of potential confounding variables (including age, gender, BMI, educational level, smoking, drinking and household income) in this study.

All statistical analyses were performed by SPSS 22.0 (IBM Corp, Armonk, NY, USA). The P-values < 0.05 were considered statistically significant.

**RESULTS**

**Distribution of Variables in Different Groups**
The characteristics of the 1,143 residents are summarized in **Table 1**. As compared to the non-diabetic group, the T2DM group have a lower proportion of men/women, drinking and vegetables intake (≥500 g/day), and a higher proportion of illiteracy and family diabetes history (\(P < 0.05\)). Besides, the average age, BMI, TG and TC in T2DM group were higher than those in non-diabetic group (\(P < 0.05\)). The distributions of household incomes, ESRα promoter methylation, HDL-C and LDL-C are comparable between the two groups.

After stratifying the participants according to the tertiles of age, we found that found that the levels of ESRα methylation, FPG and LDL-C in the elderly were elevated (all \(P < 0.05\)). There is no statistically significant difference in the levels of TG, TC, HDL-C among different groups (**Supplementary Table 2**).

**Association Between ESRα Methylation Level and Lipid Metabolism**
As shown in **Table 2**, the HDL-C level showed a downward trend with the increase of the ESRα promoter methylation level regardless of gender stratification (\(P\) for trend < 0.05). Besides, we found that in the continuous analysis, the ESRα promoter

| Characteristics | T2DM group (\(n = 237\)) | Nondiabetic group (\(n = 906\)) | \(t/z^2\) | \(P\) |
|-----------------|--------------------------|-----------------------------|---------|------|
| Age (years)     | 57.58 ± 8.96            | 54.50 ± 10.08              | 4.588   | <0.001 |
| Gender          | 6.195 0.013             |                             |         |      |
| Men             | 103 (43.5)              | 476 (52.5)                 |         |      |
| Women           | 134 (56.5)              | 430 (47.5)                 |         |      |
| BMI (kg/m²)     | 26.35 ± 3.70            | 25.62 ± 3.58               | 2.785   | 0.005 |
| Education level | 10.951 0.012            |                             |         |      |
| Illiteracy      | 51 (21.6)               | 121 (13.4)                 |         |      |
| Primary school  | 65 (27.5)               | 246 (27.2)                 |         |      |
| Junior high school | 93 (39.4)            | 406 (44.9)                 |         |      |
| High school and above | 27 (11.4) | 131 (14.5)                 |         |      |
| Smoking         | 1.875 0.171             |                             |         |      |
| Yes             | 75 (31.6)               | 330 (36.4)                 |         |      |
| No              | 162 (68.4)              | 575 (63.6)                 |         |      |
| Drinking        | 6.040 0.014             |                             |         |      |
| Yes             | 34 (14.3)               | 195 (21.5)                 |         |      |
| No              | 203 (85.7)              | 711 (78.5)                 |         |      |
| Vegetables intake (g/day) | 8.728 0.003 | 306 (33.8)                 |         |      |
| ≥ 500           | 56 (23.7)               | 180 (76.3)                 | 0.826   | 0.662 |
| < 500           | 182 (76.3)              | 600 (66.2)                 |         |      |
| Household income (RMB/year) | 0.015 | 5.869 | 182 (76.8) | 670 (74.0) | | 12 (5.1) | 54 (6.0) |
| Family diabetes history | 5.869 0.015 | 5.869 | 5.869 | 12 (5.1) | 54 (6.0) |
| Yes             | 52 (22.2)               | 140 (15.6)                 |         |      |
| No              | 182 (77.8)              | 760 (84.4)                 |         |      |
| ESRα methylation (%) | 4.58 ± 2.22 | 4.53 ± 2.21 | 0.338 | 0.735 |
| FPG (mmol/L)    | 8.65 (6.68, 10.99)      | 4.81 (4.33, 5.34)          | 20.08   | <0.001 |
| TG (mmol/L)     | 2.28 ± 1.67             | 1.72 ± 1.29                | 4.746   | <0.001 |
| TC (mmol/L)     | 4.77 ± 1.05             | 4.58 ± 0.97                | 2.558   | 0.011 |
| HDL-C (mmol/L)  | 1.22 ± 0.31             | 1.24 ± 0.30                | 0.653   | 0.514 |
| LDL-C (mmol/L)  | 2.59 ± 0.83             | 2.59 ± 0.75                | 0.999   | 0.322 |

RMB, China Yuan.

\*Data are expressed as the mean ± SD or Median (P25, P75) for continuous variables and n (%) for categorical variables.
TABLE 2 | Association between ESRα methylation and lipid metabolism.

| ESRα methylation (%) | Alla | Menb | Womenc | P for interactionc |
|-----------------------|------|------|--------|-------------------|
|                       | β (95% CI) | P  | β (95% CI) | P  | β (95% CI) | P |
| TG (mmol/L)           |      |      |        |      |      |      |
| Quartile 1            |      |      |        |      |      |      |
| Quartile 2            |      |      |        |      |      |      |
| Quartile 3            |      |      |        |      |      |      |
| Quartile 4            |      |      |        |      |      |      |
| Trend test            |      |      |        |      |      |      |
| Increase per SD       |      |      |        |      |      |      |
| TC (mmol/L)           |      |      |        |      |      |      |
| Quartile 1            |      |      |        |      |      |      |
| Quartile 2            |      |      |        |      |      |      |
| Quartile 3            |      |      |        |      |      |      |
| Quartile 4            |      |      |        |      |      |      |
| Trend test            |      |      |        |      |      |      |
| Increase per SD       |      |      |        |      |      |      |
| HDL-C (mmol/L)        |      |      |        |      |      |      |
| Quartile 1            |      |      |        |      |      |      |
| Quartile 2            |      |      |        |      |      |      |
| Quartile 3            |      |      |        |      |      |      |
| Quartile 4            |      |      |        |      |      |      |
| Trend test            |      |      |        |      |      |      |
| Increase per SD       |      |      |        |      |      |      |
| LDL-C (mmol/L)        |      |      |        |      |      |      |
| Quartile 1            |      |      |        |      |      |      |
| Quartile 2            |      |      |        |      |      |      |
| Quartile 3            |      |      |        |      |      |      |
| Quartile 4            |      |      |        |      |      |      |
| Trend test            |      |      |        |      |      |      |
| Increase per SD       |      |      |        |      |      |      |

SD, standard deviation.
aAdjusted for age, gender, BMI, educational level, smoking, drinking, household income.
bAdjusted for age, BMI, educational level, smoking, drinking, household income.
cThe interaction between ESRα methylation and gender.

methylation level was negatively associated with HDL-C levels whether gender stratification was performed (all \( P < 0.05 \)). For each unit standard deviation (SD) increment in ESRα promoter methylation, the level of HDL-C decreased by 0.03 mmol/L in all participants, 0.04 mmol/L in men and 0.03 mmol/L in women. Besides, we observed an increase of 0.08 mmol/L of LDL-C in men with each unit SD increment in ESRα promoter methylation level (\( P = 0.037 \)).

## Association Between Lipid Metabolism and T2DM

The association between lipid metabolism and T2DM is presented in Table 3. The risk of T2DM shown an upward trend with increasing quartiles of TG whether gender stratification was performed (all \( P \) for trend < 0.05). In continuous analysis, after adjusting for potential confounding factors, each unit SD increase in TG was associated with an increase of 43%, 36% and 49% in the risk of T2DM in all population, men and women respectively (all \( P < 0.05 \)).

In addition, the risk of T2DM shown a downward trend with increasing levels of HDL-C in men (\( P \) for trend < 0.05). In continuous analysis, we observed a decrement of 25% in the risk of T2DM with each unit SD increase of HDL-C levels in men. Furthermore, the interactive effect between HDL-C and gender on the risk of T2DM was evaluated, and significant association was observed.

## The Role of ESRα Methylation in the Association Between Lipid Metabolism and T2DM

We did not find any association between ESRα promoter methylation and FPG (Supplementary Table 3) or T2DM (Table 4). After stratifying the population into two groups by the ESRα promoter methylation level, we found that the risk
of T2DM in participants with lower methylation (≤ 4.07%) were more susceptible to HDL-C (P for interaction = 0.030), as manifested by a decreased of 22% in the risk of T2DM with the increment of each unit SD in HDL-C concentration (Table 5).

## DISCUSSION

In the current study, we explored the demographic information of the demographic information and found that the prevalence of T2DM in men is significantly lower than in women. Several previous studies have also observed gender differences in the prevalence of T2DM (24–26). Among them, a large-scale epidemiological survey found that the risk of T2DM in male farmers in rural areas is lower than in female farmers (26). The physical activity has been reported to mitigate the impaired glucose tolerance caused by unhealthy lifestyle (such as sleep loss) (27) and prevent the occurrence of T2DM (28). Farmers were recruited as participants in our study. And the level of physical activity of male farmers is significantly higher than that of female farmers (29), which may lead to a lower prevalence of T2DM in men.

Besides, the association between ESRα promoter methylation and lipid metabolism was investigated. And negative correlations were observed between ESRα promoter methylation and HDL-C levels, whether gender stratification was performed. Considering that the ESRα promoter methylation can suppress the protein expression of ESRα (30), we speculate that the ESRα levels may relate positively to the HDL-C levels in adults. These findings are similar to the previous studies (12, 31). The expression of LDL receptor has been reported to depend on tyrosine kinase and protein kinase C activation, both signal pathways could be activated by estrogen (32). Additionally, as a regulator of LDL-C metabolism, ESRα can affect the gene expression of LDL-C receptors (33). Whereas Knopp et al. (34) observed a lesser change in low-density lipoprotein in women than men with high-carbohydrate or high-fat feeding. Here, we only observed

### Table 3: Association between lipid metabolism and T2DM.

| Lipid metabolism (mmol/L) | T2DM | All | Men | Women | P for interaction |
|---------------------------|------|-----|-----|-------|------------------|
| **TG**                    |      |     |     |       |                  |
| Quartile 1                | OR (95% CI) | P   | OR (95% CI) | P   | OR (95% CI) | P   |
| Quartile 2                | 1.65(1.02, 2.69) | 0.42 | 2.33(1.06, 5.11) | 0.035 | 1.32(0.68, 2.54) | 0.413 |
| Quartile 3                | 1.52(1.05, 2.21) | 0.027 | 1.53(0.86, 2.74) | 0.149 | 1.41(0.85, 2.33) | 0.179 |
| Quartile 4                | 2.30(1.59, 3.33) | <0.001 | 2.64(1.49, 4.65) | 0.001 | 1.91(1.16, 3.14) | 0.011 |
| Trend test               | <0.001 |     | <0.001 |     | 0.111 |       |
| Increase per SD          | 1.43(1.25, 1.64) | <0.001 | 1.36(1.13, 1.64) | 0.001 | 1.49(1.21, 1.83) | <0.001 |

| **TC**                   |      |     |     |       |                  |
| Quartile 1                | OR (95% CI) | P   | OR (95% CI) | P   | OR (95% CI) | P   |
| Quartile 2                | 1.18(0.76, 1.83) | 0.468 | 1.42(0.75, 2.70) | 0.284 | 0.74(0.38, 1.43) | 0.368 |
| Quartile 3                | 1.26(0.82, 1.95) | 0.293 | 1.17(0.61, 2.24) | 0.630 | 1.17(0.63, 2.16) | 0.625 |
| Quartile 4                | 1.39(0.90, 2.13) | 0.134 | 1.17(0.72, 2.64) | 0.355 | 1.21(0.66, 2.22) | 0.530 |
| Trend test               | 0.121 |     | 0.467 |     | 0.486 |       |
| Increase per SD          | 1.15(0.99, 1.33) | 0.061 | 1.03(0.84, 1.29) | 0.722 | 1.18(0.96, 1.45) | 0.121 |

| **HDL-C**                |      |     |     |       |                  |
| Quartile 1                | OR (95% CI) | P   | OR (95% CI) | P   | OR (95% CI) | P   |
| Quartile 2                | 0.90(0.60, 1.34) | 0.593 | 0.82(0.46, 1.45) | 0.489 | 0.98(0.54, 1.77) | 0.941 |
| Quartile 3                | 0.81(0.54, 1.24) | 0.331 | 0.66(0.35, 1.22) | 0.184 | 0.99(0.54, 1.81) | 0.977 |
| Quartile 4                | 0.91(0.59, 1.41) | 0.679 | 0.47(0.22, 0.97) | 0.041 | 1.55(0.86, 2.81) | 0.148 |
| Trend test               | 0.478 |     | 0.010 |     | 0.168 |       |
| Increase per SD          | 0.99(0.85, 1.15) | 0.862 | 0.75(0.58, 0.97) | 0.028 | 1.18(0.97, 1.44) | 0.097 |

| **LDL-C**                |      |     |     |       |                  |
| Quartile 1                | OR (95% CI) | P   | OR (95% CI) | P   | OR (95% CI) | P   |
| Quartile 2                | 0.58(0.36, 0.92) | 0.020 | 0.39(0.19, 0.81) | 0.011 | 0.70(0.36, 1.36) | 0.290 |
| Quartile 3                | 0.79(0.51, 1.22) | 0.282 | 0.78(0.42, 1.43) | 0.423 | 0.55(0.28, 1.09) | 0.085 |
| Quartile 4                | 0.87(0.57, 1.34) | 0.527 | 0.69(0.36, 1.32) | 0.262 | 0.98(0.53, 1.82) | 0.957 |
| Trend test               | 0.923 |     | 0.532 |     | 0.976 |       |
| Increase per SD          | 0.94(0.81, 1.10) | 0.452 | 0.89(0.70, 1.12) | 0.318 | 0.95(0.76, 1.17) | 0.614 |

**SD**: standard deviation.

---

1 Adjusted for age, gender, BMI, educational level, smoking, drinking, household income.
2 Adjusted for age, BMI, educational level, smoking, drinking, household income.
3 The interaction between lipid metabolism and gender.
TABLE 4 | Association between \( \text{ESRa} \) methylation and T2DM.

| \( \text{ESRa} \) methylation (%) | All\( ^a \) | Men\( ^a \) | Women\( ^a \) |
|---------------------------------|----------|----------|----------|
|                                | OR (95% CI) | \( P \) | OR (95% CI) | \( P \) | OR (95% CI) | \( P \) |
| Quartile 1 Reference            | Reference | Reference | Reference |
| Quartile 2                      | 1.20 (0.77, 1.86) | 0.429 | 1.53 (0.80, 2.93) | 0.200 | 1.14 (0.60, 2.17) | 0.693 |
| Quartile 3                      | 1.01 (0.64, 1.58) | 0.974 | 0.94 (0.47, 1.88) | 0.851 | 1.05 (0.57, 1.96) | 0.868 |
| Quartile 4                      | 0.94 (0.59, 1.49) | 0.778 | 1.35 (0.64, 2.84) | 0.427 | 0.70 (0.38, 1.30) | 0.259 |
| Trend test                      |            |          |          |          |            |          |
| Increase per SD                 | 0.95 (0.81, 1.11) | 0.486 | 1.10 (0.86, 1.41) | 0.440 | 0.82 (0.67, 1.02) | 0.070 |

\( SD, \) standard deviation.

\( ^a \)Adjusted for age, gender, BMI, educational level, smoking, drinking, household income.

\( ^b \)Adjusted for age, BMI, educational level, smoking, drinking, household income.

TABLE 5 | Interactive effects of \( \text{ESRa} \) methylation and lipid metabolism indexes on T2DM.

| Lipid metabolism | Groups | \( \text{ESRa} \) methylation | \( \text{T2DM} \)\( ^a \) |
|------------------|--------|-----------------------------|----------------|
| TG               | &le;4.07% | 1.34 (1.08, 1.65) | 0.007 |
|                  | &gt;4.07% | 1.67 (1.34, 2.09) | &lt;0.001 |
| TC               | &le;4.07% | 1.10 (0.89, 1.36) | 0.390 |
|                  | &gt;4.07% | 1.22 (0.98, 1.53) | 0.082 |
| HDL-C            | &le;4.07% | 0.78 (0.61, 1.00) | 0.048 |
|                  | &gt;4.07% | 1.04 (0.83, 1.31) | 0.736 |
| LDL-C            | &le;4.07% | 1.02 (0.81, 1.28) | 0.878 |
|                  | &gt;4.07% | 0.88 (0.69, 1.13) | 0.322 |

\( ^a \)Adjusted for age, gender, BMI, educational level, smoking, drinking, household income.

\( ^b \)The interaction between lipid metabolism and \( \text{ESRa} \) methylation.

a positive correlation between \( \text{ESRa} \) promoter methylation and LDL-C levels in men, whereas no association was observed in women, further suggesting that LDL-C may be affected by genetic factors in a gender-specific manner.

The concentrations of LDL-C in patients with T2DM are generally not significantly different from those in non-diabetic patients (35). Similarly, no significant association between the levels of LDL-C and the risk of T2DM was observed in the present study. This may be caused by the management of LDL-C or the reduction of LDL-C catabolism in patients (8, 36). Besides, we found that the risk of T2DM was positively associated with TG whether gender stratification was performed. Besides, we observed a negative correlation between HDL-C levels and the risk of T2DM in men, instead of women. As revealed in the previous study (37), the dominant lipid abnormality in diabetes ishypertriglyceridemia, which is commonly associated with a reduction in HDL-C. Our findings are similar to the previous study, suggesting that TG and HDL-C may be closely related to the risk of T2DM. Hanai et al. (38) found that the levels of HDL-C were associated with the progression of diabetic kidney disease in men but not in women. In addition, a greater difference in those with diabetes compared with those without diabetes were observed in women than in men for HDL-C (39). Combining these findings, we speculate that there may be gender difference in relationship between HDL-C and T2DM, and a relatively small alteration in HDL-C may trigger the occurrence of T2DM in male.

A previous study found that the level of \( \text{ESRa} \) promoter methylation in decidual tissue of Germans with gestational diabetes mellitus (GDM) is higher than that of Germans without GDM (40), indicating that \( \text{ESRa} \) promoter methylation may increase the risk of GDM. While in this study, we did not observe any association between \( \text{ESRa} \) promoter methylation and FPG or the risk of T2DM. These inconsistencies may be due to the obvious difference races and different types of diabetes mellitus. Notably, many reproducible studies found that the polymorphisms in the same site (rs1801282 in \( \text{PPARG} \) gene) is not significantly associated with the risk of GDM, while it can elevate the risk of T2DM (41), suggesting that the same genetic changes may have different associations.
with different types of diabetes mellitus (42, 43). Finally, we observed a significant interactive effect of ESRα promoter methylation and HDL-C on the risk of T2DM, indicating that the level of ESRα methylation may modify the association between HDL-C and the risk of T2DM, and the risk of T2DM in participants with lower ESRα methylation is more susceptible to the alteration of HDL-C. Different DNA fragments located in the same gene may have different methylation levels and thus result in different biological effects (44). Consequently, further comprehensive methylation sequencing in large population may provide more clues for the pathogenesis of T2DM.

CONCLUSION

In summary, lipid metabolism was associated with the levels of ESRα promoter methylation and the risks of T2DM. Additionally, ESRα promoter methylation can modify the association of HDL-C and T2DM.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The project was approved by the Institutional Review Board of Zhengzhou University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LW, HH, WL, CW, and YB designed the research. GZ, XL, RS, and ZL collected the data. RS and LL performed the experiments. GZ and LL analyzed the data and wrote the manuscript. YB revised the language/article. All authors read and approved the final manuscript.

FUNDING

This study was supported by the National Natural Science Foundation of China (81972981 and 81673116) and Key Projects of Colleges and Universities of Henan Education Department (21A330006). The sponsors were not involved in research design, information collection, data analysis, or paper writing.

ACKNOWLEDGMENTS

We are sincerely grateful to all participants for their contribution.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2021.578134/full#supplementary-material

REFERENCES

1. Wang Z, Sun J, Han R, Fan D, Dong X, Luan, Z, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, Obes Metab. (2018) 20:113–20. doi: 10.1111/dob.13047
2. Zhang X, Liu J, Jin K, Xu H, Wang C, Zhang, Zh. et al. Subcutaneous injection of hydrogen gas is a novel effective treatment for type 2 diabetes. J Diabetes Invest. (2018) 9:83–90. doi: 10.1111/jdi.12674
3. Vijayakumar G, Manghat S, Vijayakumar R, Simon L, Scaria LM, Vijayakumar, A, et al. Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort. BMC Public Health. (2019) 19:140. doi: 10.1186/s12889-019-6445-6
4. Yan L, Xu MT, Yuan L, Chen B, Xu ZR, Guo, QH, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China. J Clin Lipidol. (2016) 10:150–60. doi: 10.1016/j.jcllip.2015.10.009
5. Verges, B. Pathophysiology of diabetic dyslipidemia: where are we? Diabetologia. (2015) 58:886–99. doi: 10.1007/s00125-015-3525-8
6. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. (2007) 104:12587–94. doi: 10.1073/pnas.0705408104
7. Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. (2019) 19:1500. doi: 10.1186/s12889-019-7827-5
8. Siciliani R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzio AM, et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta Diabetologica. (2018) 55:209–18. doi: 10.1007/s00592-017-1089-4
9. Khor VK, Dhur R, Yin X, Ahima RS, Song WC. Estrogen sulfotransferase regulates body fat and glucose homeostasis in female mice. Am J Physiol Endocrinol Metab. (2010) 299:E657–64. doi: 10.1152/ajpendo.00790.2009
10. Vogel H, Mirhashemi F, Liehl B, Taugner F, Kluth O, Kluge R, et al. Estrogen deficiency aggravates insulin resistance and induces β-cell loss and diabetes in female New Zealand obese mice. Horm Metab Res. (2013) 45:430–5. doi: 10.1055/s-0032-1331700
11. Gupte AA, Pownall HJ, Hamilton DJ. Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res. (2015) 2015:916585. doi: 10.1155/2015/916585
12. Khristi V, Ratri A, Ghosh S, Pathak D, Boroshia S, Dai E, et al. Disruption of ESR1 alters the expression of genes regulating hepatic lipid and carbohydrate metabolism in male rats. Mol Cell Endocrinol. (2019) 490:47–56. doi: 10.1016/j.mce.2019.04.005
13. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. (2015) 38:173–88. doi: 10.1210/er.2016-1146
14. Mauvais-Jarvis F. Menopause, estrogens, and glucose homeostasis in women. Acta Exp Med Biol. (2017) 1045:217–25. doi: 10.1007/978-3-319-70178_3_11
15. Meyer MR, Clegg DJ, Prossnitz ER, Barton, M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiologica. (2011) 203:259–69. doi: 10.1111/j.1744-1716.2010.02237.x
Zhou et al.

ESRa-Methylation, Diabetes and Lipid Metabolism

16. Ribas V, Nguyen MT, Henstridge DC, Nguyen AK, Bean SW, Watt MJ, et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice. *Am J Physiol Endocrinol Metab.* (2010) 298:E304–19. doi: 10.1152/ajpendo.00504.2009

17. Maekawa R, Mihara Y, Sato S, Okada M, Tamura I, Shinagawa M, et al. Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometriosis. *J Ovarian Res.* (2019) 12:14. doi: 10.1186/s13048-019-0489-1

18. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA1c levels in human pancreatic islets. *Diabetologia.* (2011) 54:360–7. doi: 10.1007/s00125-010-1967-6

19. Papikian A, Liu W, Gallego-Bartolomé J, Jacobsen SE. Site-specific manipulation of Arabidopsis loci using CRISPR-Cas9 SunTag systems. *Nat Commun.* (2019) 10:729. doi: 10.1038/s41467-019-08736-7

20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabetic Med.* (1998) 15:539–53. doi: 10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s

21. Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. *Analyst.* (1972) 97:142–5. doi: 10.1039/an7297000142

22. Yu Z, Armant O, Fischer R. Fungi use the SakA (HogA) pathway for phytochrome-dependent light signalling. *Nat Microbiol.* (2016) 1:16019. doi: 10.1038/nmicrobiol.2016.19

23. Lu L, Katsaros D, Rigault de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. *Cancer Res.* (2007) 67:10117–22. doi: 10.1158/0008-5472.can-07-2544

24. Choi SE, Liu M, Palaniappan LP, Wang EL, Wong ND. Gender and ethnic differences in the prevalence of type 2 diabetes among Asian subgroups in California. *J Diabetes Complications.* (2013) 27:429–35. doi: 10.1016/j.jdiacomp.2013.01.002

25. Chang H-Y, Hsu C-C, Pan W-H, Liu W-L, Cheng JY-C, Tseng C-H, et al. Gender differences in trends in diabetes prevalence from 1993 to 2008 in Taiwan. *Diabetes Res Clin Pract.* (2010) 90:358–64. doi: 10.1016/j.diabres.2010.09.032

26. Liu X, Mao Z, Li Y, Wu W, Zhang X, Hoo W, et al. Cohort profile: the henan cohort study of chronic noncommunicable diseases. *Int J Epidemiol.* (2019) 48:1756. doi: 10.1093/ije/dyz039

27. Saner NJ, Lee MJ, Kwang J, Pitchford NW, Roach GD, Garnham A, et al. Exercise mitigates sleep loss-induced changes in glucose tolerance, mitochondrial function, sarcoplasmic protein synthesis, and diurnal rhythms. *J Appl Physiol.* (2020) 10:1110–20. doi: 10.1152/japplphysiol.00110.2019

28. Baik I, Park SI. Associations of alcohol consumption and physical activity with cholesterol in cholesterol-FED male rabbits treated with estrogen. *Atherosclerosis.* (1981) 38:255–65.

29. Distefano E, Marino M, Gillette JA, Hanstein B, Pallottini V, Brüning J, et al. Role of tyrosine kinase signaling in estrogen-induced LDL receptor gene expression in HepG2 cells. *Biochim Biophys Acta.* (2002) 1580:145–9. doi: 10.1016/s1388-1981(01)00197-4

30. Brüning JC, Lingohr P, Gillette J, Hanstein B, Avcı H, Krone W, et al. Estrogen receptor-α and Sp1 interact in the induction of the low density lipoprotein receptor. *J Steroid Biochem Mol Biol.* (2003) 86:113–21. doi: 10.1016/s0960-0760(03)00263-2

31. Knopp RH, Parsons JF, Rzepkla MM, Fisher B, Walden C, Dowdy A, et al. Gender differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. *Curr Atheroscler Rep.* (2005) 7:472–9. doi: 10.1007/s11883-005-0065-6

32. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. *Diabetes Obes Metab.* (2003) 5:19–27. doi: 10.1046/j.1462-8902.2003.03010.x

33. Verge R. Lipid modification in type 2 diabetes: the role of LDL and HDL. *Fundam Clin Pharmocol.* (2009) 23:681–5. doi: 10.1111/j.1472-8206.2009.00739.x

34. Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes.* (2016) 23:150–6. doi: 10.1097/MED.0000000000000241

35. Hanai K, Babazono T, Yoshida N, Nyumura I, Toya K, Hayashi T, et al. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients. *Nephrol Dial Transplantation.* (2012) 27:1070–7. doi: 10.1093/ndt/gfr417

36. Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Strong heart study. *Diabetes Care.* (1998) 21:1258–65. doi: 10.2337/diabcare.21.8.1258

37. Knab J, Hiden U, Hüttenbrenner R, Riedel C, Hutter S, Kirn V, et al. GDM alters expression of placental estrogen receptor α in a cell type and gender-specific manner. *Reprod Sci.* (2015) 22:1488–95. doi: 10.1097/MRS.0000000000000211

38. Mao H, Li Q, Gao S. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. *PLoS ONE.* (2012) 7:e58822. doi: 10.1371/journal.pone.0058822

39. Anna M, Lluis G, Jose-Manuel FR, Joan V, Inmaculada S, Cristina G, et al. Mannose-binding lectin gene polymorphisms are associated with gestational diabetes mellitus. *J Clin Endocrinol Metab.* (2004) 89:5081–7. doi: 10.1210/jc.2004-0211

40. Gu HF. Genetic variation screening and association studies of the adenylate cyclase activating polypeptide 1 (ADCYAP1) gene in patients with type 2 diabetes. *Hum Mutat.* (2010) 19:572–6. doi: 10.1002/humu.9034

41. Fabrizio FP, Sparaneo A, Centra F, Trombetta D, Storlazzi CT, Graziano P, et al. Methyltyrosine density pattern of KEAP1 gene in lung cancer cell lines detected by quantitative methylation specific PCR and pyrosequencing. *Int J Mol Sci.* (2019) 20:2697. doi: 10.3390/ijms20112697

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.